Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 09, 2023

SELL
$0.12 - $0.3 $1,206 - $3,017
-10,058 Reduced 5.28%
180,504 $21,000
Q4 2022

Feb 09, 2023

BUY
$0.09 - $0.16 $14,625 - $26,000
162,506 Added 579.22%
190,562 $19,000
Q3 2022

Nov 09, 2022

BUY
$0.14 - $1.07 $269 - $2,056
1,922 Added 7.35%
28,056 $4,000
Q2 2022

Aug 10, 2022

SELL
$0.88 - $1.73 $74,729 - $146,911
-84,920 Reduced 76.47%
26,134 $23,000
Q1 2022

May 09, 2022

SELL
$1.14 - $2.09 $43,298 - $79,380
-37,981 Reduced 25.48%
111,054 $138,000
Q4 2021

Feb 09, 2022

BUY
$1.67 - $2.76 $186,647 - $308,471
111,765 Added 299.88%
149,035 $291,000
Q3 2021

Nov 09, 2021

BUY
$2.62 - $3.45 $21,143 - $27,841
8,070 Added 27.64%
37,270 $102,000
Q2 2021

Aug 10, 2021

BUY
$1.96 - $3.15 $57,232 - $91,980
29,200 New
29,200 $0

Others Institutions Holding VTGN

About VistaGen Therapeutics, Inc.


  • Ticker VTGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 206,836,000
  • Market Cap $720M
  • Description
  • VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III d...
More about VTGN
Track This Portfolio

Track Principal Financial Group Inc Portfolio

Follow Principal Financial Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.